Aridis touts positive preclinical results for COVID-19 mAb treatment
October 19, 2020 -- Anti-infective therapies firm Aridis Pharmaceutical has developed an inhalable highly neutralizing monoclonal antibody (mAb) that eradicated the novel coronavirus in infected rodents.
Akron, Synairgen partner on IFN-beta treatment for COVID-19
October 19, 2020 -- Cell therapeutics company Akron Biotechnology and respirator drug development firm Synairgen have partnered to advance interferon-beta (IFN-beta) treatment for patients with COVID-19.
Ultimovacs touts positive early clinical results for universal cancer vaccine
October 19, 2020 -- Ultimovacs reported five-year overall survival data from its phase I clinical trial evaluating UV1, a universal cancer vaccine candidate, in patients with non-small cell lung cancer.
Samsung Biologics, BioEleven partner on cancer immunotherapy
October 19, 2020 -- Samsung Biologics has entered into a strategic partnership with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.
Reaction Biology, 4HF Biotec offer new cell-based services
October 19, 2020 -- Reaction Biology and 4HF Biotec announced that they are offering a new cell-based service that will give customers a comprehensive understanding of their candidates. The service will combine Reaction's ProLiFiler cell assay service with 4HF's Biomarker Analysis and Mode of Action (MoA) Finder tools
OneOncology launches OneR, precision oncology research network
October 19, 2020 -- OneOncology has formed a subsidiary named OneOncology Research Network (OneR) as a national nonexclusive clinical trial site management organization to enhance research programs underway at participating community oncology practices.
Oncopeptides submits IND for peptide drug conjugate platform
October 19, 2020 -- Oncopeptides has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for OPD5, a second drug candidate based on its proprietary peptide drug conjugate platform.
Endo to acquire BioSpecifics
October 19, 2020 -- Endo will acquire all shares of BioSpecifics Technologies for $88.50 per share, or an estimated total of $540 million. As part of the acquisition, BioSpecifics will receive a royalty stream from Endo's collagenase-based therapies, including Xiaflex and Qwo, which were developed by BioSpecifics.
Bristol Myers Squibb advances cancer immunotherapy in Europe
October 16, 2020 -- The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Bristol Myers Squibb's nivolumab (Opdivo).
CHMP recommends approval for Janssen's mAb in psoriatic arthritis
October 16, 2020 -- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval for the expanded use of guselkumab (Tremfya), a monoclonal antibody (mAb) from the Janssen Pharmaceutical Companies of Johnson & Johnson.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter